- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | SAB Biotherapeutics, Inc.: SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director | 2 | GlobeNewswire (USA) | ||
| 07.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.12.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential | 5 | Investing.com | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | SAB Biotherapeutics, Inc.: First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D | 276 | GlobeNewswire (Europe) | Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 17.12.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D | 214 | GlobeNewswire (Europe) | Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteersStudy results support the chronic dosing... ► Artikel lesen | |
| 15.12.25 | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.11.25 | SAB BioTherapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 13.11.25 | SAB Biotherapeutics, Inc.: SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights | 143 | GlobeNewswire (Europe) | Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites activated; on-track to dose first patient by year-endRecent... ► Artikel lesen | |
| 30.09.25 | SAB Biotherapeutics verkleinert Verwaltungsrat nach Rücktritt von zwei Direktoren | 9 | Investing.com Deutsch | ||
| 26.09.25 | SAB Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 22.09.25 | SAB Biotherapeutics stock maintains Buy rating at H.C. Wainwright on positive diabetes treatment data | 2 | Investing.com | ||
| 19.09.25 | SAB Biotherapeutics, Inc.: SAB BIO Highlights Data in Multiple Presentations at EASD | 1 | GlobeNewswire (USA) | ||
| 03.09.25 | SAB Biotherapeutics, Inc.: SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes | 2 | GlobeNewswire (USA) | ||
| 09.05.25 | SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates | 565 | GlobeNewswire (Europe) | MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 31.03.25 | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results | 605 | GlobeNewswire (Europe) | MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 162,45 | +0,06 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 45,000 | -0,44 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,342 | -0,92 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,155 | -0,18 % | Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| EXELIXIS | 37,260 | -0,11 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,438 | +0,86 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARDIOL THERAPEUTICS | 0,920 | +6,11 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,630 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,100 Euro und damit -0,49 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.